Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines

详细信息    查看全文

• 作者：Somayeh Talebi^a ; ¹ ; Azam Bolhassani^a ; ¹ ; ^{azam.bolhassani@yahoo.com} ; ^{A_bolhasani@pasteur.ac.ir} ; Seyed Mehdi Sadat^a ; Rouhollah Vahabpour^b ; Elnaz Agi^a ; Sepideh Shahbazi^a
• 关键词：HPV ; Vaccine ; Adjuvant ; HMGB1 nuclear protein ; Hp91 peptide
• 刊名：Biomedicine & Pharmacotherapy
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：85
• 期：Complete
• 页码：148-154
• 全文大小：1389 K
• 卷排序：85

文摘

High percentage of human cervical malignancy is related to human papillomavirus (HPV) infections. Thus, it is important to find novel non-invasive treatment strategies among various therapeutic HPV vaccines. In current study, we investigated the protective and therapeutic effects of DNA- and protein-based vaccines using HPV16 E7 as a model antigen in tumor mice model. In this line, the full length of high-mobility group box 1 (HMGB1) protein as well as an HMGB1-derived short peptide (Hp91) was used as an adjuvant for stimulating adaptive immunity and developing the potency of these vaccines.MethodsDNA vaccination of HPV16 E7 with HMGB1 was performed as the complexed and conjugated forms. The immunostimulatory properties of Hp91 peptide along with Hp121 control peptide were compared to Montanide 720 in protein vaccination.ResultsOur data showed that co-immunization of HPV16 E7 protein with Hp91 peptide or Hp91 + Hp121 peptides significantly increased the secretion of IFN-γ, IgG2a antibody response, and protected 100% of mice against a TC-1 tumor challenge. Furthermore, the linkage of HMGB1 with E7 antigen led to enhance the immunogenicity of DNA vaccine especially in combination with Hp91 and Hp121 peptides.ConclusionsThese findings suggest that Hp91 peptide, and the full length of HMGB1 gene could be an efficient adjuvant for improvement of therapeutic HPV protein- and DNA-based vaccines, respectively.